Annual incidence of HCC in HCV-related cirrhotic or pre-cirrhotic liver is reported as 4-8%, and IFN-α treatment is estimated to reduce approximately 50% of annual incidence of HCC in chronic hepatitis C with cirrhotic or pre-cirrhotic liver, if SVR rate of approximately 30% is achieved. The gene discussed is IFNA1; the disease is chronic hepatitis C virus infection.